GlobeNewswire (Mon, 4:30PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
486 people get SUPN articles and Market Currents by email alert.
Get email alerts on SUPN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (May 6, 2013)
-
-
GlobeNewswire (Apr 26, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
-
-
-
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 1, 2013)
-
-
-
GlobeNewswire (Jan 14, 2013)
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
ACRX Falls On Financing, Creating Opportunity Ahead Of Phase III DataPropThink • Thu, Dec 6, 2012 -
-
-
-
-
-
-
-
-
2012 Biotech IPOs: Age Of The Dreamers?Bioassociate Consulting • Wed, Jul 4, 2012 -
-
-
-
-
GlobeNewswire (Mon, 4:30PM)
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (Apr 26, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 1, 2013)
-
GlobeNewswire (Jan 14, 2013)
-
GlobeNewswire (Nov 29, 2012)
-
GlobeNewswire (Nov 20, 2012)
-
GlobeNewswire (Nov 19, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Nov 5, 2012)
-
GlobeNewswire (Oct 31, 2012)
-
GlobeNewswire (Oct 22, 2012)
-
GlobeNewswire (Aug 29, 2012)
-
GlobeNewswire (Aug 10, 2012)
-
GlobeNewswire (Jul 20, 2012)
SUPN vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. Our extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization,... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 13, 4:07 PM Supernus Pharmaceuticals (SUPN): Q1 EPS of -$0.60 beats by $0.11. Revenue of $147K misses by $423K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, April 26, 11:53 AM Supernus Pharmaceuticals (SUPN +10.6%) moves up after pricing its $75M offering of convertible senior secured notes due 2019. The company intends to use approximately $21M million of the net proceeds to repay in full its borrowings under and terminate its secured credit facility and the remainder of the net proceeds to fund the commercialization of its approved and tentatively approved drugs, Oxtellar XR and Trokendi XR, and to continue development of its pipeline. Comment! [Healthcare, On the Move]
- Wednesday, April 24, 6:03 PM Supernus Pharmaceuticals (SUPN) announces a private offering of $75M in Convertible Senior Notes due 2019, with a 30-day option to purchase up to an additional $15M. The notes are being secured by liens on substantially all of SUPN's assets. Shares -14% AH. Comment! [Healthcare, On the Move]
-
Wednesday, April 24, 5:52 PM
After-hours top gainers, as of 5:15 p.m.: AKAM +16%. FIO +12%. AVG +10%. ANGI +8%. BYI +6%.
After-hours top losers: SUPN -14%. CTXS -12%. EQIX -11%. INTU -10%. ZNGA -8%. Comment! [On the Move] -
Tuesday, March 26, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: MXWL +9%. SAI +4%. OWW +3%. SPLK +3%. SUPN +3%.
After-hours top losers: LNDC -8%. ACMP -4%. EOG -4%. PXD -3%. LOGM -3%. 1 Comment [On the Move] - Thursday, March 14, 4:57 PM Supernus Pharmaceuticals (SUPN): Q4 EPS of -$0.51 beats by $0.20. Revenue of $1.09M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
-
Friday, November 30, 2012, 1:04 PM
Midday top 10 gainers: MARK +38%. MITL +30%. MHH +25%. CBK +24%. PPHM +24%. AMPL +24%. TELK +19%. PLNR +17%. TLAB +15%. FIVE +15%.
Top 10 Losers: RIC -24%. NTLS -23%. FFKY -19%. SUPN -18%. SBLK -14%. VRSN -14%. PSUN -14%. MMYT -13%. HGSH -13%. PWX -11%. Comment! [On the Move] - Friday, November 30, 2012, 7:45 AM Supernus Pharmaceuticals (SUPN) dives 16% after pricing a 6M secondary at just $8/share. The stock was trading at $11 late yesterday afternoon. (PR) Comment! [Healthcare, On the Move]
- Monday, October 22, 2012, 1:38 PM Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite receiving approval from the FDA for its epilepsy treatment, Oxtellar XR, a once-daily extended release formulation of oxcarbazepine. The FDA also granted a waiver for the pediatric study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children one month to 6 years of age. Comment! [Healthcare]
-
Monday, October 22, 2012, 9:10 AM
Premarket gainers: PGRX +42%. SUPN +16%. SVU +7%. ACOM +8%. OREX +7%. NBG +6%. BTU +6%. PHG +6%. GIVN +6%.
Losers: OSG -50%. NXY -7%. Comment! [On the Move] -
Wednesday, June 27, 2012, 9:05 AM
Premarket gainers: ENTR +25%. AMRN +15%. SUPN +8%. WPRT +8%.
Losers: ORLY -17%. OMER -16%. CCG -6%. Comment! [On the Move] -
Tuesday, June 26, 2012, 9:10 AM
Premarket gainers: SUPN +38%. SCMF +12%. NWSA +7%. APOL +6%.
Losers: JRCC -8%. LDK -7%. Comment! [On the Move] - Tuesday, June 26, 2012, 8:28 AM Supernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment for epilepsy. Final authorization is conditional on Supernus resolving a marketing exclusivity issue regarding a specific pediatric population. The FDA also denies a Citizen's Petition filed in 2011 by Upsher Smith Labs related to its NDA on Trokendi XR. Comment! [Healthcare, On the Move]
-
Chemistfrog
$SUPN I believe entry down here is wise. Q1 financials could really give the company momo.. Final approval for Trokendi in June/July - View all 2 replies
-
joe kelly: You have any opinion on cytk? Keeps coming up on my radar along with supn. -
Chemistfrog: $CYTK chart is in breakout mode. Many catalysts ahead for 13. Watch earnings release for phase IIb update.. I like the company. Good future.
-
- View all 1 replies
-
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/MAjrXs Premarket gainer $ENTR (23%), $AMRN(11.32%), $SUPN(8%), $PWRD(5%) - View all 0 replies
LATEST REPLIES
-
Chemistfrog
$SUPN I believe entry down here is wise. Q1 financials could really give the company momo.. Final approval for Trokendi in June/July - View all 2 replies
-
joe kelly: You have any opinion on cytk? Keeps coming up on my radar along with supn.
-
Chemistfrog: $CYTK chart is in breakout mode. Many catalysts ahead for 13. Watch earnings release for phase IIb update.. I like the company. Good future.
-
- View all 1 replies
-